Al Abed, Y; Zhang, L (October 2020) Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia. .
Abstract
This disclosure generally relates to treating anemias. More specifically, the disclosure relates to use of muscarinic acetylcholine receptor subtype 4 antagonists, such as small molecule compounds, to promote self-renewal of burst forming unit erythroid (BFU-E) cells and treat anemias.
| Item Type: | Patent |
|---|---|
| Subjects: | diseases & disorders > anemia |
| CSHL Authors: | |
| Communities: | CSHL labs > Zhang L. lab |
| SWORD Depositor: | CSHL Elements |
| Depositing User: | CSHL Elements |
| Date: | 1 October 2020 |
| Date Deposited: | 17 Aug 2021 15:03 |
| Last Modified: | 17 Aug 2021 15:03 |
| URI: | https://repository.cshl.edu/id/eprint/40324 |
Actions (login required)
 |
Administrator's edit/view item |
